News on Kamada ltd from BioPortfolio.com http://www.BioPortfolio.com Consolidated Kamada ltd news from BioPortfolio.com Wed, 10 Feb 2010 13:03:03 GMT en Kamada Announces Enrollment Of First Patient In Its Pivotal Study For Inhaled AAT In Europehttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4039685&HITNO=0&MSIZE=12&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Kamada%20ltd&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4039685&THISHREF=http://c.moreover.com/click/here.pl%3fz2538321789%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4039685&HITNO=0&MSIZE=12&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Kamada%20ltd&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4039685&THISHREF=http://c.moreover.com/click/here.pl%3fz2538321789%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comMedical News Today: Kamada initiates enrollment in Phase II/III study of inhalable AAT drughttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4039978&HITNO=1&MSIZE=12&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Kamada%20ltd&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4039978&THISHREF=http://c.moreover.com/click/here.pl%3fz2538504786%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4039978&HITNO=1&MSIZE=12&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Kamada%20ltd&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4039978&THISHREF=http://c.moreover.com/click/here.pl%3fz2538504786%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmacy Choice: Medical News: Kamada Announces Enrollment Of First Patient In Its Pivotal Study For Inhaled AAT In Europehttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4040373&HITNO=2&MSIZE=12&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Kamada%20ltd&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4040373&THISHREF=http://c.moreover.com/click/here.pl%3fz2538712451%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4040373&HITNO=2&MSIZE=12&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Kamada%20ltd&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4040373&THISHREF=http://c.moreover.com/click/here.pl%3fz2538712451%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comBioFind: Kamada Announces Enrollment of First Patient in Its Pivotal Study for Inhaled AAT in Europehttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4032207&HITNO=3&MSIZE=12&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Kamada%20ltd&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4032207&THISHREF=http://c.moreover.com/click/here.pl%3fz2534545101%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4032207&HITNO=3&MSIZE=12&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Kamada%20ltd&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4032207&THISHREF=http://c.moreover.com/click/here.pl%3fz2534545101%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comYahoo! Canada: Kamada Announces Enrollment of First Patient in Its Pivotal Study for Inhaled AAT in Europehttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4037052&HITNO=4&MSIZE=12&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Kamada%20ltd&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4037052&THISHREF=http://c.moreover.com/click/here.pl%3fz2536879771%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4037052&HITNO=4&MSIZE=12&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Kamada%20ltd&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4037052&THISHREF=http://c.moreover.com/click/here.pl%3fz2536879771%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPipelineReview: Kamada initiates enrollment in Phase II/III study of inhalable AAT drughttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4035192&HITNO=5&MSIZE=12&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Kamada%20ltd&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4035192&THISHREF=http://c.moreover.com/click/here.pl%3fz2536155250%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4035192&HITNO=5&MSIZE=12&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Kamada%20ltd&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4035192&THISHREF=http://c.moreover.com/click/here.pl%3fz2536155250%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comTherapeutics Daily: Kamada commences enrollment in European inhaled AAT clinical trial for alpha-1 antitrypsin deficiencyhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033287&HITNO=6&MSIZE=12&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Kamada%20ltd&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033287&THISHREF=http://c.moreover.com/click/here.pl%3fz2535101033%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033287&HITNO=6&MSIZE=12&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Kamada%20ltd&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033287&THISHREF=http://c.moreover.com/click/here.pl%3fz2535101033%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comNews-Medical.Net: Kamada Announces Enrollment of First Patient in Its Pivotal Study for Inhaled AAT in Europehttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4031628&HITNO=7&MSIZE=12&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Kamada%20ltd&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4031628&THISHREF=http://c.moreover.com/click/here.pl%3fz2534280901%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4031628&HITNO=7&MSIZE=12&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Kamada%20ltd&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4031628&THISHREF=http://c.moreover.com/click/here.pl%3fz2534280901%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharma Live: Kamada Announces Enrollment of First Patient in Its Pivotal Study for Inhaled AAT in Europehttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4029736&HITNO=8&MSIZE=12&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Kamada%20ltd&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4029736&THISHREF=http://c.moreover.com/click/here.pl%3fz2533248249%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4029736&HITNO=8&MSIZE=12&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Kamada%20ltd&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4029736&THISHREF=http://c.moreover.com/click/here.pl%3fz2533248249%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comGenetic Engineering News: Kamada Announces Enrollment of First Patient in Its Pivotal Study for Inhaled AAT in Europehttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4029700&HITNO=9&MSIZE=12&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Kamada%20ltd&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4029700&THISHREF=http://c.moreover.com/click/here.pl%3fz2533238252%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4029700&HITNO=9&MSIZE=12&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Kamada%20ltd&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4029700&THISHREF=http://c.moreover.com/click/here.pl%3fz2533238252%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comGenetic Engineering News: BRIEF: Kamada wins FDA nod for shortened rabies trial: The shortened clinical trial will slash development costs and time to register and market the company's rabies vaccine in the US.http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3937859&HITNO=10&MSIZE=12&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Kamada%20ltd&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3937859&THISHREF=http://c.moreover.com/click/here.pl%3fz2483718564%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3937859&HITNO=10&MSIZE=12&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Kamada%20ltd&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3937859&THISHREF=http://c.moreover.com/click/here.pl%3fz2483718564%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comIndividual.com: Globes, Tel Aviv, Israel, Gali Weinreb column: 2010 is a crucial year for biomed [Globes, Tel Aviv, Israel]http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3855672&HITNO=11&MSIZE=12&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Kamada%20ltd&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3855672&THISHREF=http://c.moreover.com/click/here.pl%3fz2442040832%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3855672&HITNO=11&MSIZE=12&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Kamada%20ltd&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3855672&THISHREF=http://c.moreover.com/click/here.pl%3fz2442040832%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comTherapeutics Daily: